1 articles with this tag
<p>Dutch startup Citryll has secured €85 million in a Series B funding round, co-led by Johnson & Johnson Innovation, Forbion, and Novartis Venture Fund.</p><p>The funds will support the clinical development of CIT-013, a first-in-class antibody targeting Neutrophil Extracellular Traps (NETs), addressing severe inflammatory diseases.</p><p>This funding round also sees new board appointments from leading investors, enhancing Citryll's mission to provide innovative treatment options.</p>
